Endocrinology Today—March 24, 2026

LucidQuest

3 hours ago

This week’s Endocrinology update highlights late-stage clinical progress, generic market expansion, partnerships, novel therapeutic approaches, and diagnostic advancements shaping metabolic care.

In Today’s Newsletter

Dive deeper

💊 Retatrutide Phase 3 topline in type 2 diabetes [1] [20 Mar 2026]

https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html
Context: TRANSCEND-T2D-1 evaluated retatrutide (Eli Lilly; GIP, GLP-1, glucagon triple agonist) in adults with type 2 diabetes inadequately controlled with diet and exercise.
Key point: Lilly reported that retatrutide met the primary and all key secondary endpoints, with superior A1C reduction and weight loss versus placebo at 40 weeks.
Implication: May influence prescriber choice and payer reviews pending full data.

💉 Generic semaglutide launches in India [2] [India • 19 Mar 2026]

https://money.rediff.com/news/market/generic-semaglutide-launched-in-india-by-eris-natco/43918220260320
Context: Eris Lifesciences and Natco Pharma launched multi-dose vial formats, with pen-device launches also described in the source.
Key point: Generic semaglutide entered the Indian market after patent expiry, with both companies positioning the product for diabetes and weight management.
Implication: Introduces competition that may affect pricing and formulary access.

🤝 Lupin, Zydus sign semaglutide co-marketing deal [3] [India • 17 Mar 2026]

https://www.lupin.com/media/press-releases/lupin-and-zydus-sign-licensing-agreement-for-co-marketing-innovative-semaglutide-injection-in-india
Context: Lupin received semi-exclusive co-marketing rights for Zydus’ semaglutide injection in India, including a reusable pen device.
Key point: The companies said the agreement is intended to broaden access to semaglutide injection for metabolic disorders in India.
Implication: Signals pipeline investment and modality expansion.

🧬 GentiBio doses first participant in POLARIS [4] [US • 18 Mar 2026]

https://www.prnewswire.com/news-releases/gentibio-announces-first-participant-dosed-in-polaris-phase-1-clinical-trial-of-gnti-122-in-recently-diagnosed-type-1-diabetes-302716586.html
Context: POLARIS is a Phase 1, single-dose, open-label study of GNTI-122 in adults within 120 days of type 1 diabetes diagnosis, across 10 U.S. sites.
Key point: GentiBio announced first-participant dosing of GNTI-122, an autologous engineered regulatory T-cell therapy designed to preserve natural insulin production.
Implication: May influence prescriber choice and payer reviews pending full data.

🩺 Endogenex publishes REGENT-1 48-week results [5] [17 Mar 2026]

https://www.biospace.com/press-releases/endogenex-announces-publication-of-regent-1-clinical-study-results-in-diabetes-obesity-and-metabolism
Context: Integrated REGENT-1 Australia and REGENT-1 US analysis included 71 adults with type 2 diabetes treated with the Endogenex Pulsed Electric Field System.
Key point: Endogenex reported durable HbA1c reduction, weight loss, and a favorable safety profile through 48 weeks after a single endoscopic procedure.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧪 Redcliffe Labs launches Elecsys AMH Plus for PCOS work-up [6] [19 Mar 2026]

https://www.biospectrumindia.com/news/16/27513/redcliffe-labs-introduces-elecsys-amh-plus-blood-test-to-transform-pcos-diagnosis.html
Context: Redcliffe Labs said it launched the Elecsys AMH Plus blood test with Roche Diagnostics India to support identification of polycystic ovarian morphology.
Key point: The source text positions AMH testing as a less invasive alternative to ultrasound in PCOS evaluation, citing guideline support and validation studies.
Implication: May expand screening, initiation, and follow-up at scale.

🏢 Paratek completes Radius combination [7] [18 Mar 2026]

https://radiuspharm.com/paratek-pharmaceuticals-completes-combination-with-radius-health-expanding-its-multi-product-specialty-commercial-platform/
Context: The combination adds TYMLOS (abaloparatide) to Paratek’s commercial portfolio alongside NUZYRA and XHANCE.
Key point: Paratek said the completed Radius Health combination expands its multi-product specialty commercial platform and therapeutic reach.
Implication: Signals pipeline investment and modality expansion.

📊 Acromegaly pipeline update highlights 10+ companies [8] [20 Mar 2026]

https://www.openpr.com/news/4431929/acromegaly-clinical-trial-pipeline-accelerates-as-10-pharma
Context: The DelveInsight summary describes 10+ companies and 12+ pipeline drugs across clinical and nonclinical stages in acromegaly.
Key point: The report highlights ongoing development activity from companies including Crinetics, Alexion, Debiopharm, and others.
Implication: Signals pipeline investment and modality expansion.

Why It Matters

Incretin competition is intensifying, with both innovative and generic semaglutide strategies advancing in India.
Lilly’s retatrutide topline adds pressure to the broader obesity and diabetes landscape ahead of fuller Phase 3 readouts.
New modalities, including engineered Tregs and gut-directed endoscopic therapy, are broadening the metabolic treatment pipeline.
Diagnostics and access models remain important alongside therapeutics, as shown by the PCOS testing launch.
Specialty platform consolidation continues to reshape commercialization strategies.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

🎯 Catch up on the Top Endocrinology news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What did Lilly report for retatrutide in TRANSCEND-T2D-1?

Lilly said retatrutide met the primary and all key secondary endpoints in Phase 3, with superior A1C reduction and weight loss versus placebo at 40 weeks. Detailed results are expected later. [1]

What changed in India for semaglutide this week?

Two things happened: generic semaglutide launched after patent expiry, and Lupin signed a co-marketing deal with Zydus for branded semaglutide injection. Together, these moves could widen access and sharpen competition. [2][3]

What is GNTI-122 in type 1 diabetes?

GNTI-122 is GentiBio’s autologous engineered regulatory T-cell therapy. The first participant has now been dosed in the Phase 1 POLARIS study in recently diagnosed adults. [4]

What kind of evidence did Endogenex publish?

Endogenex reported an integrated analysis from REGENT-1 Australia and REGENT-1 US. The study was not described here as a randomized pivotal trial, so interpretation should remain cautious. [5]

Why is the Redcliffe Labs AMH test notable?

The source text presents it as a blood-based aid for identifying polycystic ovarian morphology in PCOS work-up, potentially reducing reliance on more invasive ultrasound-based assessment. [6]

What is the acromegaly item, news or a market report?

It is a pipeline report summary rather than a primary company trial readout. It is useful for landscape context, but it is not equivalent to a peer-reviewed study or formal company results release. [8]

Entities / Keywords

Retatrutide, Eli Lilly, TRANSCEND-T2D-1, semaglutide, Eris Lifesciences, Natco Pharma, Lupin, Zydus Lifesciences, GentiBio, GNTI-122, POLARIS, Endogenex, REGENT-1, Redcliffe Labs, Roche Diagnostics India, Elecsys AMH Plus, PCOS, Paratek Pharmaceuticals, Radius Health, TYMLOS, acromegaly, Crinetics, Alexion, Debiopharm